Credit Suisse’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-135,629
| Closed | -$142K | – | 2946 |
|
|
2023
Q4 | $142K | Buy |
135,629
+36,522
| +37% | +$38.3K | ﹤0.01% | 3001 |
|
|
2023
Q3 | $679K | Buy |
99,107
+4,463
| +5% | +$30.6K | ﹤0.01% | 2509 |
|
|
2023
Q2 | $981K | Buy |
94,644
+28,352
| +43% | +$294K | ﹤0.01% | 2377 |
|
|
2023
Q1 | $536K | Buy |
66,292
+1,320
| +2% | +$10.7K | ﹤0.01% | 2692 |
|
|
2022
Q4 | $1.02M | Buy |
64,972
+23,580
| +57% | +$371K | ﹤0.01% | 2318 |
|
|
2022
Q3 | $652K | Buy |
41,392
+4,450
| +12% | +$70.1K | ﹤0.01% | 2611 |
|
|
2022
Q2 | $515K | Buy |
36,942
+4,990
| +16% | +$69.6K | ﹤0.01% | 2802 |
|
|
2022
Q1 | $550K | Buy |
31,952
+3,222
| +11% | +$55.5K | ﹤0.01% | 2897 |
|
|
2021
Q4 | $418K | Buy |
28,730
+1,038
| +4% | +$15.1K | ﹤0.01% | 3142 |
|
|
2021
Q3 | $499K | Buy |
27,692
+1,725
| +7% | +$31.1K | ﹤0.01% | 2986 |
|
|
2021
Q2 | $456K | Buy |
+25,967
| New | +$456K | ﹤0.01% | 3075 |
|
|
2019
Q3 | – | Sell |
-51,593
| Closed | -$113K | – | 3421 |
|
|
2019
Q2 | $113K | Buy |
51,593
+18,153
| +54% | +$39.8K | ﹤0.01% | 3293 |
|
|
2019
Q1 | $200K | Buy |
33,440
+134
| +0.4% | +$801 | ﹤0.01% | 3174 |
|
|
2018
Q4 | $245K | Buy |
33,306
+9,849
| +42% | +$72.5K | ﹤0.01% | 3065 |
|
|
2018
Q3 | $340K | Sell |
23,457
-16,725
| -42% | -$242K | ﹤0.01% | 3000 |
|
|
2018
Q2 | $802K | Buy |
40,182
+7,563
| +23% | +$151K | ﹤0.01% | 2729 |
|
|
2018
Q1 | $571K | Buy |
32,619
+1,859
| +6% | +$32.5K | ﹤0.01% | 2890 |
|
|
2017
Q4 | $759K | Buy |
30,760
+6,086
| +25% | +$150K | ﹤0.01% | 2715 |
|
|
2017
Q3 | $637K | Buy |
24,674
+14,477
| +142% | +$374K | ﹤0.01% | 2937 |
|
|
2017
Q2 | $276K | Buy |
10,197
+637
| +7% | +$17.2K | ﹤0.01% | 3117 |
|
|
2017
Q1 | $286K | Sell |
9,560
-9,691
| -50% | -$290K | ﹤0.01% | 3156 |
|
|
2016
Q4 | $524K | Buy |
+19,251
| New | +$524K | ﹤0.01% | 3067 |
|